福岡がん総合クリニック

業績紹介メニュー

免疫療法関係論文

  1. MORISAKI T,HIRANO T,KOYA N,KIYOTA A,TANAKA H,UMEBAYASHI M,ONISHI H and KATANO M
    「NKG2D-directed Cytokine-activated Killer Lymphocyte Therapy Combined with Gemcitabine for Patients with Chemoresistatic Solid Tumors」
    ANTICANCER RESEARCH 34:4529-4538(2014)

    標準治療耐性の進行がんに対するジェムザールと活性化リンパ球の併用療法の効果とそのメカニズムを示した当院からの最新の論文です。

  2. UMEBAYASHI M ,AKIFUMI K,KOYA N,TANAKA H,ONISHI H, KATANO M and MORISAKI T
    「An Epithelial Cell Adhesion Molecule-and CD3-Bispecific Antibody Plus Activated T-Cells Can Eradicate Chemoresistant Cancer Stem-like Pancreatic Carcinoma Cells In Vitro」
    ANTICANCER RESEARCH34:4509-4520(2014)
  3. Onishi H, Morisaki T, Kiyota A, Koya N, Tanaka H, Umebayashi M, Katano M
    The Hedgehog inhibitor suppresses function of monocyte-derived dendritic cells from patients with advanced cancer under hypoxia.
    Biochem Biophys Res Common.2013 Jun 21;436(1):53-9.
  4. Onishi H, Morisaki T(※1), Nakao F, Odate S, Morisaki T(※2), Katano M
    Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition hedgehog signaling and HIF -1αpathways under hypoxia.
    CancerLeft.2013 Jul 28;335(2):289-98.
    (※1:Morisaki Takafumi ※2:Morisaki Takashi)
  5. Onishi H, Morisaki T, Kiyota A, Koya N, Tanaka H, Umebayashi M, Katano M
    The hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer.
    Cancer Immunol Immunother,2013 Jun;62(6):1029-39.
  6. Suzuki H, Onishi H, Morisaki T, Tanaka M, Katano M
    Intratumoral FOXP3+VEGFR2+regulatory T cells arepredictive markers for recurrence and survival in patients with colorectal cancer.
    Clin Immunol. 2013 Jan;146(1):26-33.
  7. Onishi H,Koya N,Kiyota A,Tanaka H,Umebayasi M,Katano M,and Morisaki T
    A New Method for Rapid Cytotoxic T-lymphocyte Induction Using a Multiple Cytokine Cocktail
    ANTICANCER RESEARCH32:2385-2390(2012)
  8. Morisaki T, Umebayasi M, Kiyota A, Koya N, Tanaka H, Onishi H, and Katano M
    Combining Cetuximab with Killer Lymphocytes Synergistically Inhibits Human Cholangiocarcinoma Cells In Vitro
    ANTICANCER RESEARCH 32:2249-2256(2012)
  9. Morisaki T, Onishi H, and Katano M
    Cancer Immunotherapy Using NKG2D and DNAM-1 Systems
    ANTICANCER RESEARCH 32: 2241-2248(2012)
  10. Morisaki T, Onishi H, Koya N, et al.
    Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcionoma via the NKG2D-MICA/B system
    Anticancer Res 31:2505-2510,2011
  11. Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K, Morisaki T, Katano M.
    VEGFR2 is selectively expressed by FOXP3high CD4+ Treg.
    Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
    Eur J Immunol.2010 Jan;40(1):197-203.
  12. Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, Katano M.
    Intratumoral CD8(+) T/FOXP3(+) cell ratio is a predictive marker for survival in patients with colorectal cancer.
    Cancer Immunol Immunother.2010 May;59(5):653-61. Epub 2009 Nov 12.
  13. Wada J, Onishi H, Suzuki H, Yamasaki A, Nagai S, Morisaki T, Katano M.
    Surface-bound TGF-beta1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-cells in malignant effusions.
    Anticancer Res. 2010 Sep;30(9):3747-57.
  14. Yamasaki A, Kameda C, Xu R, Tanaka H, Tasaka T, Chikazawa N, Suzuki H, Morisaki T, Kubo M, Onishi H, Tanaka M, Katano M.
    Nuclear factor kappaB-activated monocytes contribute to pancreatic cancer progressiion through the production of Shh.
    Cancer Immunol Immunolher.2010 May;59(5):675-86. Epub 2009 Oct 28.
  15. Wada J, Suzuki H, Fuchino R, Yamasaki A, Nagai S, Yanai K, Koga K, Nakamura M, Tanaka M, Morisaki T, Katano M.
    The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.
    Anticancer Res. 2009 Mar;29(3):881-8.
  16. Yamasaki A, Shoda M, Iijima H, Nagai S, Wada J, Suzuki H, Chikazawa N, Tasaka T, Kameda C, Tanaka H, Ikebe M, Jo E, Sato N, Nakamura M, Sekine F, Morisaki T, Katano M.
    A protein-bound polysaccharide, PSK, enhances tumor suppression induced by docetaxel in a gastric cancer xenograft model.
    Anticancer Res. 2009 Mar;29(3):843-50.
  17. Nakamura M, Wada J, Suzuki H, Tanaka M, Katano M, Morisaki T. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Anticancer Res. 2009 Mar;29(3):831-6.
  18. Wada J, Yamasaki A, Nagai S, Yanai K, Fuchino K, Kameda C, Tanaka H, Koga K, Nakashima H, Nakamura M, Tanaka M, Katano M, Morisaki T.
    Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients.
    Anticancer Res. 2008 Jul-Aug;28(4C):2401-8.
  19. Tatsugami K, Eto M, Harano M, Hamaguchi M, Miyamoto T, Morisaki T, Furue M, Akashi K, Naito S.
    Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma.
    Int J Urol. 2008 Aug;15(8):694-8. Epub 2008 Jun 16.
  20. Kubo M, Morisaki T, Katano M, et al.
    Paclitaxel probably enhances cytotoxicity of natural killer cells against Breast carcinoma cells by increasing perforin production
    Cancer Immunol Immunother 54:468-476, 2005
  21. Katano M , Morisaki T, et al.
    Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Anticancer Res 25 (6A) : 3771-3776, 2005.
  22. Onishi H, Kuroki H, Katano M, Morisaki T.
    Monocyte-derived dendritic cells that capturedead tumor cells secrete IL-12 and TNF-α through IL-12/TNF-α/NF-κB autocrine loop
    Cancer Immunol Immunother 53:1093-1100, 2004
  23. Morisaki T, Matsumoto K, Onishi H, et al.
    Dendritic cell-based combined immuneotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progresss, and perspectives.
    Hum Cell 16(4):1-14,2003.

    樹状細胞療法の世界の現況と、活性化リンパ球療法の併用療法の可能性を示した総説論文。

  24. Morisaki T, Mastumoto K, Kuroki H, et al.
    Combined immunotherapy with intracavital injection of activated lymphocytes and monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
    Anticancer Res. 23:4459-4466, 2003.

    がん性腹膜炎、胸膜炎に対する局所への樹状細胞と活性化リンパ球投与併用移入療法の臨床的有用性を示した原著論文

  25. Kubo M, Morisaki T, Kuroki H, et al.
    Combination of adoptive immunotherapy with herceptin for patients with Her2-expressing breast cancer.
    Anticancer Res 23, 4443-4449, 2003.HER2

    陽性乳癌に対するハーセプチンと活性化リンパ療法との併用療法の可能性を示した原著論文。

  26. Kuroki H, Morisaki T, Matsumoto K, et al.
    Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use
    Cancer Immunol Immunother 52:561-568, 2003

    樹状細胞の成熟化、活性化における菌体製剤OK-432の有用性の可能性を示した原著論文。

  27. Morisaki T, Matsunaga H, Beppu K, et al.
    A combination of cyclosporin-A (CsA) and Interferon-gamma (IFN-g) induces apoptosis in human gastric carcinoma cells.
    Anticancer Res. 20:3363-3374,2000.
  28. Zhang H, Morisaki T, Matsunaga H, et al.
    Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.
    Clin Exp Metastasis. 2000;18(4):343-52.

    免疫増強剤(BRM)として知られるPSKが、癌細胞の浸潤能をTGF-β1とMMPの産生と活性化の抑制を介して抑制することを明らかにした。

  29. Morisaki T, Katano M, Ikubo A, et al.
    Immunosuppressive cytokines (IL-10, TGF-β) genes expression in human gastric carcinoma tissues. J. Surg. Oncol. 63:234-239, 1996

    ヒト胃癌組織においては、免疫抑制サイトカインであるTGF-β1とIL-10の発現が非がん組織よりも高いことを明らかにした。

  30. Ikubo A, Morisaki T, Katano M, et al.
    A possible role of TGF-β in the formation of malignant effusions.
    Clin. Immunol. Immunopath. 77:27-32,1995.
  31. Morisaki T, Morton D L , Uchiyama A, et al.
    Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.
    Cancer Immunol Immunother 39:172-178,1994.

    悪性黒色腫に対する自己腫瘍特異的T細胞(CTL)のうち、CD4陽性のCTLの生物学的特性をCD8 CTLとの比較に於いて明らかにした原著論文

  32. Hoon D.S.B., Morisaki T, Uchiyama A, et al.
    Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens.
    Ann New York Acad Sci 690:343-345, 1993
  33. Uchiyama A, Hoon D S B, Morisaki T, et al.
    Transfection of interleukin-2 gene into human melanoma cells augments cellular immune response
    Cancer Res. 53:949-952,1993.
  34. Uchiyama A, Morisaki T, Torisu M.
    Evidence that induction and regulation of lymphokine-activated killer (LAK) activity are mediated by changes in tumor-binding potential of lympocytes after activation by Interleukin-2 (IL-2)
    Immunology 741: 94-98, 1991.

    高濃度IL-2で活性化、増殖させたヒトLAK細胞の抗腫瘍活性の増強には接着分子LFA-1の発現増強に伴う癌細胞への接着能増強と相関することを明らかにした。

  35. Morisaki T, Yuzuki DH, Lin RT,et al.
    Interleukin4 Regulates G1 cell Cycle progression in gastric carcinoma cells Cancer Res.54,1113-1118,1994
  36. Hoon D S B, Hayashi Y, Morisaki T, et al.
    Interleukin-4 plus tumor necrosis factor a augments the antigenicity of melanoma cells.
    Cancer Immnuol. Immunother. 37:378-384,1993.
  37. Morisaki T, Yuzuki D H, Lin R T, et al.
    Interleukin-4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin-4.
    Cancer Res. 52:6059-6065, 1992.

    ヒト胃癌細胞はTリンパ球やマスト細胞が産生するサイトカインであるIL-4(インターロイキン4)の受容体の遺伝子発現ならびに膜表面での蛋白発現があり、IL-4により増殖が抑制されることを明らかにした

  38. Morisaki T, and Torisu M
    Enhanced adherence activity of OK-432-induced peritoneal nuetrophils to tumor cells correlates to their increased expression of CD11b/CD18
    Clinical immunology and immunotherapy 59,474-486,1991

抗がん剤等による薬物療法に関する論文

  1. Morisaki T, Umebayashi M , Kiyota A, Koya N, Tanaka H, Onishi H, Katano M
    Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Anticancer Res.2013 Apr;33(4):1387-95.
  2. Nakashima H , Tasakai A , Morisaki T, et al. Effects of docetaxel on antigen presentation-related functions of human monocyte-derived dendritic cells. Cancer Chemother Pharmacol. 55(5) : 479-487, 2005.
  3. Yamanaka N, Morisaki T, Katano M, et al Interleukin-1b enhances invaisive ability of gastric carcinoma through nuclear factor-kB activation Clin Cancer Res 10:1853-1859, 2004
  4. Beppu K, Morisaki T, Matsunaga H, et al.:Inhibition of interferon-γ-activated nuclear factor-κB by cyclosporin A: a possible mechanism for synergistic induction of apoptosis by interferon-γ and cyclosporin A in a gastric carcinoma cells. Biochem Biophys Res Comm. 305:797-805, 2003.
  5. Zhang H, Morisaki T, Nakahara C, Matsunaga H, Sato N, Nagumo F, Tadano J, Katano M. PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1.. Oncogene. 22:2088-2096, 2003
  6. Nakahara C, Nakamura K, Yamanaka N, Baba E, Wada M, Matsunaga H, Noshiro H, Tanaka M, Morisaki T, Katano M.:Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in human gastric carcinoma cells.Clin Cancer Res. 9: 5409-5416, 2003.
  7. Kuga H, Morisaki T, Nakamura K, et al.:Interferon-γ suppresses transforming factor-β-induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model. Oncogene 22: 7838-7847, 2003 .

    ヒト胃癌の三次元人工組織をin vitroで再構築し、このモデルを用いて、スキルス胃癌における浸潤能へのTGF-β1の関与と、IFN-γ(インターフェロンガンマ)によるその抑制メカニズムを分子生物学的に明らかにした。

  8. Morisaki T, Katano M.: Mitochondria-targeting therapeutic strategies for overcoming chemoresistance and progression of cancer. Curr Med Chem 10:2517-2521, 2003.

    ミトコンドリアは細胞内においてATP産生に関わる重要な細胞内小器官であるが、通常の抗がん剤耐性の癌細胞が、このミトコンドリアを標的とした薬剤により傷害されることが明らかになってきた。本総説は、その研究、臨床における世界の現況をReviewしたものである。

  9. HAO LUO、Umebayashi M, Doi K, Morisaki T, Shirasawa S, Tsunoda T Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells Anticancer Research36:3585-3590(2016)

和文総説

  1. 大西秀哉、荻野利達、森崎 隆、片野光男 がん局所微小環境と免疫療法 患者さんを見据えた全人的癌治療 ー低酸素環境とHedgehog Signalー 癌と化学療法 Vol.44 2017年11月
  2. 森崎 隆 「特集:併用療法による新たな展開」(Biotherapy:Vol.24 No.4 291-295)で『総説:分子標的薬剤と免疫』を執筆, July 2010
  3. 森崎 隆、田中裕人、他 NKG2Dを介した癌細胞認識機構と免疫細胞療法Biotherapy:24(1) 40-45, 2010
  4. 森崎 隆 免疫療法と化学療法併用による総合的癌治療―その理論と実際Biotherapy:23(4)295-301, 2009
  5. 片野光男、和田純治、鈴木宏往、山崎章生、大西秀哉、森崎 隆 腫瘍免疫と制御性T細胞 Biotherapy23:(3)245-255, 2009
  6. 森崎 隆、和田純治、渕野亮太、片野光男 癌免疫療法における経時的な制御性T細胞比率測定の臨床的意義 Biotherapy21:(5) 348-353, 2007
  7. 森崎 隆、佐々木暢彦、片野光男:癌におけるNF-κB活性化の臨床的意義;症における発癌と癌悪性化への関与: 放射線生物研究 37(4) 453-464, 2002.
  8. 森崎 隆、片野光男 「スキルス」胃癌の免疫療法ー特に再発例について外科治療 Vol 86, No6, 1096-1103, 2002
  9. 森崎 隆、片野光男、田中雅夫:消化器癌に対する補助療法「専門医のための消化器外科レビュー2001」総合医学社
  10. 森崎 隆、小島雅之、片野光男:がん治療の分子標的としてのNF-κBの意義 最新医学 56:3, 35-43, 2001
  11. 森崎 隆、片野光男 癌におけるNF-kBの活性化と抗アポトーシス機構 Cancer Frontier 2(1),42-50,2000.

がんに関する著書(分担執筆)

  1. Hoon D S B, Morisaki T, Essner R. Inhibition of nonhemopoietic cancer cell growth by Interleukin-4 and related cytokines. 219-240, In “Tumor Immunology: Immunotherapy and cancer vaccine”Edited by Dalgleish A G, Browning M J. Cambridge University Press. (Cambridge)1996
  2. 森崎 隆、井久保 丹、片野光男 2. Th1/Th2バランス外科領域における癌免疫療法ーその理論と実際ー 仁尾義則、片野光男ライフサイエンス・メディカ p25-p33
  3. 片野光男、森崎 隆 4.免疫学を基盤とした癌性腹膜炎治療 外科領域における癌免疫療法ーその理論と実際ー 仁尾義則、片野光男ライフサイエンス・メディカ p44-p58
  4. 片野光男、森崎 隆 がん性漿膜炎3. がん性腹膜炎、がん性腹水 臨床腫瘍学 p101-p108
ページのトップへ戻る